Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis
Table 1
Characteristics of the included studies.
First author
Year
Country
Patient number
Detection method
Mean age (years)
Media follow-up (mounts)
Outcome
Mucins phenotype
Antibody
Cut-off value (high level)
High MUC expression
Adams
2009
Switzerland
938
IHC
70.5
128.0
OS
MUC2
NR
NR
Al-Maghrabi
2019
Saudi Arabia
128
IHC
NR
NR
OS/DFS
MUC2
MRQ-18
36.7%
Baldus
2000
Germany
264
IHC
64.8
NR
OS
MUC1
NCL-MUC1
58.0%
Baldus
2004
Germany
205
IHC
65.0
NR
OS
MUC1
HMFG-2
49.8%
Betge
2016
Germany
381
IHC
68.5
NR
OS/DFS
MUC1
Ma695
64.0%
MUC2
Ccp-58
77.0%
MUC5AC
45M1
48.9%
MUC6
MCN6.01
28.7%
Dawson
1987
UK
358
IHC
65.7
18.0
OS
Sialomucin
High iron diamine-alcian blue
Blue staining
29.6%
Diaz
2018
Spain
96
IHC
65.9
NR
DFS
MUC1
Clone E29
46.0%
Duncan
2007
UK
403
IHC
72.0
116.0
OS
MUC1
Ma695
31.5%
MUC3
1143/B7
73.9%
Elzagheid
2013
Libya
141
IHC
NR
77.0
OS/DFS
MUC2
MRQ-18
50.0%
Hiraga
1998
Japan
100
IHC
62.7
80.0
OS
MUC1
KL-6
71.0%
Imai
2013
Japan
250
IHC
66.9
NR
OS/RFS
MUC2
Ccp-58
49.4%
MUC5AC
CLH2
46.8%
Ionescu
2014
Romania
39
qRT-PCR
66.0
NR
OS
MUC12
NR
NR
NR
Kang
2011
Korea
229
IHC
NR
108
OS
MUC2
NR
24.2%
Kasprzak
2018
Poland
34
IHC
NR
NR
OS
MUC1
Ma552
100%
MUC2
Ccp-58
100%
Khanh
2013
Japan
206
IHC
NR
NR
OS/RFS
MUC1
Ma695
62.6%
MUC2
Ccp-58
32.5%
MUC4
1G8
33.0%
MUC5AC
CLH2
33.5%
Kimura
2000
Japan
110
IHC
63.1
68.5
OS
MUC1
KL-6
69.1%
Kocer
2002
Turkey
41
IHC
56.3
NR
DFS
MUC5AC
45M1
34.1%
Kocer
2006
USA
30
IHC
59.0
39.0
OS
MUC5AC
45M1
60.0%
Lennerz
2016
USA
33
IHC
58.0
51.2
OS
MUC2
Ccp58
84.0%
MUC5AC
CLH2
45.0%
MUC6
CLH5
0.0%
Manne
2000
USA
166
IHC
65.3
NR
OS
MUC1
DF3
39.8%
MUC2
Ccp58
80.7%
Matsuda
2010
Japan
569
IHC
68.0
NR
OS
MUC2
Anti-MUC2
65.0%
MUC5AC
Anti-MUC5
15.1%
MUC6
Anti-MUC6
1.9%
Matsuyama
2010
Japan
100
qRT-PCR
65.1
27.0
DFS
MUC12
Rabbit polyclonal antibody
NR
NR
Perez
2008
Brazil
35
IHC
62.2
NR
OS/DFS
MUC1
Ma695
20.0%
MUC2
Ccp-58
65.7%
MUC5AC
CLH2
22.9%
Shanmugam
2010
USA
132
IHC
65.0
NR
OS
MUC4
Clone 8G7
24.2%
Sun
2018
China
118
IHC
54.3
57.0
OS/DFS
MUC1
MXB Biotechnologies
14.4%
Streppel
2012
USA
39
IHC
63.6
NR
OS
MUC16
Monoclonal antibody
64.1%
Wang
2016
China
81
IHC
63.5
NR
OS
MUC1
ZM-0391
53.1%
Wang
2017
China
139
IHC
NR
NR
OS
MUC2
NCL-MUC2
48.2%
MUC5AC
NCL-MUC5
28.1%
Xiao
2013
China
150
IHC
55.0
NR
OS/DFS
MUC20
Mouse antihuman polyclonal antibody
60.7%
You
2006
China
203
IHC
NR
111.9
OS
MUC1
Ma695
40.7%
Yu
2007
China
150
IHC
57.5
NR
OS
MUC1
Ma695
45.3%
MUC2
Ccp-58
52.6%
MUC5AC
45M1
44.0%
Zhang
2008
Japan
77
IHC
64.9
NR
OS
MUC1
KL-6
SI (positive)
55.8%
Zwenger
2014
Argentina
90
IHC
NR
NR
OS
MUC1
HMFG1
94.0%
MUC2
H300
52.4%
NR: not reported; RT-PCR: reverse transcriptase polymerase chain reaction; IHC: immunohistochemistry; SI: staining intensity; PP: positive cell percentage; immunostaining score (ISS): PPSI (while groups I and II (absent and low) were considered negative expression).
